Indications
Cefaclor is indicated for the treatment of specific bacterial infections. These include ailments such as pneumonia, as well as infections of the ear, lung, skin, throat, and urinary tract. The medication is targeted towards bacterial pathogens that are susceptible to this antibiotic.
Pharmacodynamics
Cefaclor functions as a second-generation cephalosporin antibiotic with a spectrum of activity similar to that of first-generation cephalosporins. Its bactericidal effect is achieved through the inhibition of bacterial cell-wall synthesis. Extensive in vitro and in vivo clinical studies have demonstrated its efficacy against a variety of Gram-positive aerobes, including Staphylococci (both coagulase-positive and coagulase-negative strains, along with penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Additionally, it is effective against Gram-negative aerobes such as Escherichia coli, Haemophilus influenzae (even those strains resistant to ampicillin due to ß-lactamase production), Klebsiella species, and Proteus mirabilis.
Absorption
Cefaclor is efficiently absorbed following oral administration, with its absorption largely unaffected by food intake. This characteristic facilitates flexible dosing schedules, thereby enhancing patient compliance.
Metabolism
Cefaclor undergoes minimal metabolic transformation in the liver. Approximately 60% to 85% of the administered dose is excreted unchanged in the urine within eight hours, indicating that renal excretion is the primary route of elimination for this drug.
Mechanism of Action
Cefaclor functions as a beta-lactam antibiotic, sharing similarities with penicillins in its mechanism of action. It targets penicillin-binding proteins (PBPs) situated within the bacterial cell wall, thereby disrupting the final stage of cell wall synthesis. This disruption leads to cell lysis, which is facilitated by the activity of autolytic enzymes like autolysins. Additionally, cefaclor may play a role in interfering with autolysin inhibitors, further promoting bacterial cell lysis.
